This single-patient case report provides incremental validation for Namodenoson in liver disease, but does not change the risk profile for the stock. Traders should monitor upcoming Phase 3 data readouts for Namodenoson in hepatocellular carcinoma and Phase 2b results in MASH, which are more material catalysts. The stock may see a modest short-term bounce on the positive press, but low liquidity and history of volatile moves warrant caution.
Price Chart
Executive Summary
Can-Fite announced the publication of a peer-reviewed case report showing that its drug Namodenoson improved decompensated cirrhosis symptoms (resolution of ascites, regression of esophageal varices) in a single patient, who remained stable for ~28 months and successfully bridged to liver transplantation. This is a supportive but non-definitive data point for Namodenoson's potential in advanced liver disease, given it is a single-patient observation.
Key Facts
- Peer-reviewed case report published in Japanese Journal of Gastroenterology and Hepatology on September 9, 2026
- Patient with advanced decompensated cirrhosis treated with Namodenoson experienced resolution of ascites and regression of esophageal varices
- Patient remained clinically stable for ~28 months and underwent successful liver transplantation in January 2026
- Namodenoson is currently in a pivotal Phase 3 trial for advanced liver cancer and Phase 2b trial for MASH
Financial Impact
Not specified
Risk Factors
- Single-patient case report is not a clinical trial and provides limited statistical evidence
- Namodenoson still requires successful Phase 3 data before any regulatory filing
- Company has a history of losses and may require further capital raises, causing dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-098205 |
| Document: ea0304939-6k_canfite.htm | 0001213900-26-098205 |
| Document: 0001213900-26-098205-index-headers.html | 0001213900-26-098205 |
| Document: 0001213900-26-098205-index.html | 0001213900-26-098205 |
| Document: 0001213900-26-098205.txt | 0001213900-26-098205 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.95 | awaiting T+5 | — | $1.72 (−11.79%) |
Oct 13, 2026 13d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.72 (+11.79%) |
Oct 13, 2026 13d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.72 (+11.79%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.72 (+25.22%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.72 (−21.46%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.72 (−26.81%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.72 (−27.12%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.72 (+27.12%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.72 (−27.12%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.72 (−51.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers